research Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.
Search
for
Sort by
Research
30 / 402 results 
research GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
research GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity
GLP-1 receptor analogs may help improve metabolism and reproductive health in people with PCOS and obesity.
research The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
GLP-1 receptor agonists can both help and harm hair, so careful monitoring is needed.
research Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends
GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
research Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review
GLP-1 agonists may help treat certain skin conditions.
research Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.
research Dermatologic Implications of GLP-1 Receptor Agonist Medications: A Comprehensive Review
GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
research Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
GLP-1 receptor agonists may cause hair loss, but more research is needed.
research Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review
GLP-1 receptor agonists help women with PCOS lose weight and improve health, but more research is needed on long-term effects.
research Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes
GLP-1 RAs may help wound healing but can also cause faster facial aging and skin issues.
research “From evidence to practice” – Insights from the multidisciplinary team on the optimal integration of GLP ‐1 receptor agonists in obesity management services
GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.
research Methylene blue protects hair follicle stem cells from oxidative and metabolic stress to enhance hair regeneration
Methylene blue helps hair growth by protecting hair stem cells from stress.
research Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
GLP-1RAs, like semaglutide and tirzepatide, may cause hair loss, so patients should be informed and monitored.
research The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms
GLP-1RAs may cause hair loss but could also help regrow hair in some cases.
research Effects of GLP ‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review
GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
research Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
research Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
Medications for PCOS don't seem to raise heart disease risk.
research Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
research INDIVIDUALIZED TREATMENT OF POLYCYSTIC OVARY SYNDROME: A MANIFESTATION-GUIDED PRACTICAL APPROACH
PCOS treatment should be personalized based on individual symptoms and health goals.
research Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
GLP-1RA therapy may increase the risk of hair loss.
research current possible treatment approaches of Polycystic Ovary Syndrome (PCOS)
Different treatments for PCOS should be tailored to the individual, including lifestyle changes and various medications.
research The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
research GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
research Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report
A rash from semaglutide may be due to propylene glycol, not the drug itself.
research The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
The effect of GLP-1 RAs on erectile function is unclear and needs more research.
research Exploring the Role of GLP ‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review
GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
research Ann Robinson’s research reviews —12 May 2022
Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.
research Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment—A Single Center Case Series
Individualized treatments may help manage Dercum's disease symptoms.